ADVANCED PHARMACOLOGY EXAM 1
QUESTIONS AND ANSWERS 2026/2027
UPDATE || 100% GUARANTEED PASS
1. A patient with chronic renal failure is prescribed a drug that is primarily excreted via the
kidneys. Which adjustment should the Nurse Practitioner expect to make?
A. Increase the dose frequency to maintain steady state
B. No adjustment is necessary if the drug has a high protein binding
C. Switch to an oral route to delay absorption
D. Decrease the dose or increase the dosing interval
Answer: D
Conceptual Explanation: In renal failure, clearance is reduced, which increases the half-
life of drugs primarily excreted by the kidneys. To avoid toxicity, the dose should be
reduced or the interval between doses should be increased.
2. Which pharmacokinetic process is most significantly affected by the ‘first-pass effect’ in the
liver?
A. Distribution
B. Bioavailability
C. Excretion
,D. Protein binding
Answer: B
Conceptual Explanation: The first-pass effect occurs when a drug is metabolized by the
liver before reaching systemic circulation, which directly reduces the bioavailability of the
drug.
3. A drug has a half-life of 6 hours. If a patient reaches steady state, how many hours has the
drug likely been administered at a constant rate?
A. 6 to 12 hours
B. 24 to 30 hours
C. 12 to 18 hours
D. 48 to 60 hours
Answer: B
Conceptual Explanation: Steady state is generally achieved after 4 to 5 half-lives. With a
6-hour half-life, 4 to 5 half-lives equal 24 to 30 hours.
4. Which of the following describes an ‘agonist’ drug?
A. A drug that binds to a receptor and prevents activation
B. A drug that increases the metabolism of other drugs
C. A drug that binds to a receptor and produces a biological response
D. A drug that binds irreversibly to an enzyme
, Answer: C
Conceptual Explanation: An agonist mimics the action of endogenous ligands by binding
to a receptor and initiating a physiological response.
5. According to the DEA, which schedule of controlled substances has the highest potential
for abuse but also has an accepted medical use?
A. Schedule I
B. Schedule II
C. Schedule III
D. Schedule V
Answer: B
Conceptual Explanation: Schedule I drugs have no accepted medical use and high abuse
potential. Schedule II drugs have high abuse potential but are used medically under strict
regulations.
6. When prescribing a drug that is a known CYP3A4 inhibitor to a patient already taking a
CYP3A4 substrate, what is the most likely outcome?
A. Decreased therapeutic effect of the substrate
B. Rapid excretion of the substrate
C. Increased serum levels and potential toxicity of the substrate
D. Induction of liver enzymes leading to subtherapeutic levels
QUESTIONS AND ANSWERS 2026/2027
UPDATE || 100% GUARANTEED PASS
1. A patient with chronic renal failure is prescribed a drug that is primarily excreted via the
kidneys. Which adjustment should the Nurse Practitioner expect to make?
A. Increase the dose frequency to maintain steady state
B. No adjustment is necessary if the drug has a high protein binding
C. Switch to an oral route to delay absorption
D. Decrease the dose or increase the dosing interval
Answer: D
Conceptual Explanation: In renal failure, clearance is reduced, which increases the half-
life of drugs primarily excreted by the kidneys. To avoid toxicity, the dose should be
reduced or the interval between doses should be increased.
2. Which pharmacokinetic process is most significantly affected by the ‘first-pass effect’ in the
liver?
A. Distribution
B. Bioavailability
C. Excretion
,D. Protein binding
Answer: B
Conceptual Explanation: The first-pass effect occurs when a drug is metabolized by the
liver before reaching systemic circulation, which directly reduces the bioavailability of the
drug.
3. A drug has a half-life of 6 hours. If a patient reaches steady state, how many hours has the
drug likely been administered at a constant rate?
A. 6 to 12 hours
B. 24 to 30 hours
C. 12 to 18 hours
D. 48 to 60 hours
Answer: B
Conceptual Explanation: Steady state is generally achieved after 4 to 5 half-lives. With a
6-hour half-life, 4 to 5 half-lives equal 24 to 30 hours.
4. Which of the following describes an ‘agonist’ drug?
A. A drug that binds to a receptor and prevents activation
B. A drug that increases the metabolism of other drugs
C. A drug that binds to a receptor and produces a biological response
D. A drug that binds irreversibly to an enzyme
, Answer: C
Conceptual Explanation: An agonist mimics the action of endogenous ligands by binding
to a receptor and initiating a physiological response.
5. According to the DEA, which schedule of controlled substances has the highest potential
for abuse but also has an accepted medical use?
A. Schedule I
B. Schedule II
C. Schedule III
D. Schedule V
Answer: B
Conceptual Explanation: Schedule I drugs have no accepted medical use and high abuse
potential. Schedule II drugs have high abuse potential but are used medically under strict
regulations.
6. When prescribing a drug that is a known CYP3A4 inhibitor to a patient already taking a
CYP3A4 substrate, what is the most likely outcome?
A. Decreased therapeutic effect of the substrate
B. Rapid excretion of the substrate
C. Increased serum levels and potential toxicity of the substrate
D. Induction of liver enzymes leading to subtherapeutic levels
